Pfizer (PFE) Chief Strategy Officer Baum Resigns, Transitions to Advisor Role After $10 Billion Metsera Acquisition
Departure of Strategy Chief and Transition to Advisor Role
Andrew Baum, M.D., Chief Strategy and Innovation Officer (CSO), has stepped down from his position after two years and will transition to the role of Senior Strategic Advisor to Albert Bourla, Ph.D., CEO. Baum is expected to remain with Pfizer (PFE) to advise on portfolio strategy until the end of 2026 before leaving the company entirely. He joined Pfizer as a key executive from Citi, a global investment bank, where he led healthcare research, garnering industry attention. His transition and planned departure coincide with Pfizer's ongoing business restructuring, attracting significant market interest.
Financial Background: End of COVID-19 Boost and Cost-Cutting Pressures
The resignation comes amid Pfizer's significant financial challenges and pressure from shareholders. Due to the sharp decline in sales of COVID-19 products, Pfizer has been implementing a $4 billion cost-realignment program since 2024. In 2025, Pfizer's annual revenue was $62.6 billion, a decrease of $1 billion compared to the previous year. In this context, management has been streamlining the organizational structure to improve R&D funding allocation and expedite decision-making. Baum's departure is seen as part of this organizational efficiency and management reform strategy.
Metsera Acquisition: A Success in Overcoming Self-Development Failures
A key achievement during Baum's tenure was the acquisition of Metsera, a biopharmaceutical company specializing in obesity treatments, completed in November 2025. After competing with Novo Nordisk, Pfizer successfully acquired Metsera for an upfront payment of $4.9 billion, with potential milestone payments totaling up to $10 billion. This strategic acquisition aimed to offset the clinical failure of its in-house obesity drug candidate, danuglipron. Through this acquisition, Pfizer secured MET-097i, a sustained-release GLP-1 receptor agonist in Phase 2 clinical trials, and MET-233i, an amylin analog in Phase 1 clinical trials. This reflects Baum's efforts to diversify the portfolio by overcoming the limitations of internal development through external M&A.
Big Pharma's Strategic Survival Competition in the Obesity Market Gold Rush
Recently, the trend of hiring CSO's from Wall Street analysts with expertise in both clinical knowledge and financial acumen has become more prevalent in the pharmaceutical industry. Bristol Myers Squibb (BMS, BMY) is a prime example, having appointed Chris Shibutani, M.D., from Goldman Sachs as its chief strategy officer. With the global obesity treatment market projected to grow rapidly to as much as $150 billion by 2030, their ability to optimize portfolios is a critical factor in corporate survival. Baum's departure highlights the challenges of achieving long-term innovation strategies amid short-term performance pressures.
The resignation of Andrew Baum, Chief Strategy Officer (CSO) at Pfizer (PFE), is part of a leadership reorganization amid a revenue decline of $1 billion to $62.6 billion in 2025 and cost-cutting pressures of $4 billion. The key assets acquired through the Metsera acquisition, including the obesity drug candidates MET-097i (Phase 2) and MET-233i (Phase 1), will be a test of Pfizer's long-term growth potential. These assets are crucial for re-establishing its position in the rapidly growing obesity treatment market, which is expected to exceed $100 billion by 2030, in competition with Novo Nordisk's Wegovy and Eli Lilly's Zepbound. As seen with Bristol Myers Squibb (BMS, BMY) appointing Chris Shibutani from Goldman Sachs as CSO, the trend of optimizing R&D portfolios through Wall Street experts is becoming a common practice in the industry. While the departure of the strategy chief may temporarily impact pipeline development timelines, it is expected to streamline the organizational structure and accelerate R&D decision-making in the long term, thereby improving cost-effectiveness.